Korea University Study Reveals How a Blood Biomarker Tracks Response to Lecanemab in Early Alzheimer's Disease

Data ReadoutLecanemabPositive

AI Analysis

Summary

A Korea University study investigates plasma p-tau217 as a potential early biomarker for tracking treatment response to lecanemab in early Alzheimer's disease patients.

Outcome Details

Study investigates plasma p-tau217 as a potential early marker of treatment response to lecanemab

Importance:4/10

Sentiment:

0.30

Alzheimer's diseaseBiomarkerTreatment responsep-tau217LecanemabResearch study

Related Companies

$MRKR

Read the original article

Published by PR Newswire Biotech on September 14, 2026 12:44 PM

Read Original